TCGA-E2-A155-01A-11R-A12D-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 21
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.430
- G2M_CHECKPOINT+0.410
- PROTEIN_SECRETION+0.390
- E2F_TARGETS+0.360
- PEROXISOME+0.280
- ESTROGEN_RESPONSE_EARLY+0.270
- ANDROGEN_RESPONSE+0.250
- MYC_TARGETS_V1+0.220
- TGF_BETA_SIGNALING+0.210
- ESTROGEN_RESPONSE_LATE+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.520
- INTERFERON_GAMMA_RESPONSE-0.510
- ALLOGRAFT_REJECTION-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- INFLAMMATORY_RESPONSE-0.440
- IL6_JAK_STAT3_SIGNALING-0.400
- COAGULATION-0.310
- NOTCH_SIGNALING-0.310
- COMPLEMENT-0.300
- IL2_STAT5_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.911 |
| 2 | TCGA-A2-A1G4-01A-11R-A13Q-07 | — | B | 0.900 |
| 3 | TCGA-E2-A1IE-01A-11R-A13Q-07 | — | B | 0.877 |
| 4 | TCGA-HQ-A2OF-01A-11R-A26T-07 | — | — | 0.873 |
| 5 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.870 |
| 6 | 13649cf2-1dc4-408f-9063-31a2b9bb7157 | — | — | 0.861 |
| 7 | TCGA-E9-A1RE-01A-11R-A157-07 | — | B | 0.854 |
| 8 | TCGA-AQ-A04H-01B-11R-A10J-07 | — | B | 0.853 |
| 9 | GSM5359416 | — | — | 0.849 |
| 10 | TCGA-HQ-A2OE-01A-11R-A206-07 | — | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| PEROXISOME | 0.280 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |